

ONCOLOGY INNOVATION BENEFIT

DISCOVERY HEALTH MEDICAL SCHEME
2022





Overview

The Oncology Innovation Benefit gives members on all plans, except the KeyCare Plans, access to a defined list of high-cost medicines and new technologies for a defined list of cancers. Your cover depends on your chosen health plan. This benefit is not available on the KeyCare Plans.

About some of the terms we use in this document

There may be some terms we refer to in the document that you may not be familiar with. Here are the meanings of these terms.

TERMINOLOGY	DESCRIPTION
Co-payment	This is an amount that you need to pay towards a healthcare service. The amount can vary by the type of covered healthcare service, place of service or if the amount the service provider charges is higher than the rate we cover. If the benefit co-payment or upfront amount is higher than the amount charged for the healthcare service, you will have to pay for the cost of the healthcare service.
Designated service provider (DSP)	A healthcare provider (for example doctor, specialist, allied healthcare professional, pharmacist or hospital) who we have an agreement with to provide treatment or services at a contracted rate. Visit www.discovery.co.za or click on Find a healthcare provider on the Discovery app to view the full list of designated service providers (DSPs).
Discovery Health Rate (DHR)	This is a rate we pay for healthcare services from hospitals, pharmacies, healthcare professionals and other providers of relevant health services.
Precision medicine	Targeted therapies and immunotherapies guided by Next Generation Sequencing (a pathology test that identifies cancer genomic drivers). NGS is covered from the hospital benefit where clinical entry criteria is met.

Cover from the Oncology Innovation Benefit for Executive and Comprehensive plans (excluding Classic Smart Comprehensive plan).

You have cover for a defined list of cancers and precision medicine covered from the Oncology Innovation Benefit, subject to the Scheme's clinical entry criteria.

Approval is subject to meeting clinical entry criteria and requests may be reviewed by an external panel for consideration for funding from this benefit. Where approved, we will pay up to 75% of the Discovery Health Rate (DHR) for the defined list of medicines and cancers listed in the table below. If the healthcare provider charges more than the amount the Scheme pays, you will need to pay the difference. This amount could be more than 25% if your treatment cost is above the Discovery Health Rate (DHR). These claims will accumulate to your R400 000 cover amount at 75% of the Discovery Health Rate (DHR).

Once your treatment costs exceed the R400 000 cover amount, the Scheme will continue to pay 75% of the Discovery Health Rate (DHR) for approved medicine.

Cover from the Oncology Innovation Benefit for the Classic Smart Comprehensive, Priority, Saver, Smart and Core Plans

You have cover for a sub-set of the cancers and precision medicine covered from the Oncology Innovation Benefit, subject to the Scheme's clinical entry criteria. This benefit is not available on the KeyCare Plans.

Approval is subject to meeting clinical entry criteria and requests may be reviewed by an external panel for consideration for funding from this benefit. Where approved, we will pay up to 50% of the Discovery Health Rate (DHR) for the defined list of medicines and cancers listed in the table below. If the healthcare provider charges more than the amount the Scheme pays, you will need to pay the difference. This amount could be more than 50% if your treatment cost is above the Discovery Health Rate (DHR). These claims will accumulate to the R300 000 or R200 000 cover amount, depending on your chosen health plan, at 50% of the Discovery Health Rate (DHR).

Once your treatment costs exceed the R300 000 or R200 000 cover amount, the Scheme will continue to pay 50% of the Discovery Health Rate (DHR) for approved medicine.

ONCOLOGY INNOVATION BENEFIT

Discovery Health Medical Scheme, registration number 1125, is regulated by the Council for Medical Schemes and administered by Discovery Health (Pty) Ltd, registration number 1997/013480/07, an authorised financial services provider. Find a healthcare provider, Discovery MedXpress and the Discovery app are brought to you by Discovery Health (Pty) Ltd; registration number 1997/013480/07, an authorised financial services provider and administrator of medical schemes.



Defined medicines are covered from the Oncology Innovation Benefit for Comprehensive and Executive plans (excluding Classic Smart Comprehensive plan)

If you meet the Scheme's clinical entry criteria, you have cover for the following oncology medicines:

INDICATION	PRODUCT NAME	CLINICAL CRITERIA
Locally advanced or metastatic non-small cell lung cancer	Keytruda	Metastatic non-small cell lung carcinoma (NSCLC) and as first line therapy and whose tumours express PD-L1 with a $\geq 50\%$ and with no EGFR or ALK genomic tumour aberrations
	Keytruda	Metastatic Squamous non-small cell lung carcinoma (NSCLC) and in combination with carboplatin and either paclitaxel or nab-paclitaxel and as first line therapy
	Keytruda	Metastatic non-squamous non-small cell lung carcinoma (NSCLC) and in combination with pemetrexed and platinum chemotherapy and as first line therapy and with no EGFR or ALK genomic tumour aberrations
	Keytruda	Advanced non-small cell lung carcinoma (NSCLC) and as second line therapy after platinum-containing chemotherapy and whose tumours express PD-L1 with a $\geq 1\%$ TPS If EGFR or ALK genomic tumour aberration, After one line of targeted therapy
	Tagrisso	Locally advanced or metastatic non-small cell lung cancer (NSCLC) and as second line therapy (after EGFR TKI therapy) and EGFR T790M mutation-positive
	Tecentriq	Metastatic non-squamous non-small cell lung cancer and in combination with bevacizumab, paclitaxel and carboplatin and with no EGFR or ALK genomic tumour aberrations as first line therapy or if EGFR or ALK genomic tumour aberrations, as second line therapy (after appropriate targeted therapy).
	Xalkori	Advanced non-small cell lung carcinoma (NSCLC) and whose tumours are ALK positive and as first line therapy or second line therapy after failure of systemic chemotherapy

ONCOLOGY INNOVATION BENEFIT

Discovery Health Medical Scheme, registration number 1125, is regulated by the Council for Medical Schemes and administered by Discovery Health (Pty) Ltd, registration number 1997/013480/07, an authorised financial services provider. Find a healthcare provider, Discovery MedXpress and the Discovery app are brought to you by Discovery Health (Pty) Ltd; registration number 1997/013480/07, an authorised financial services provider and administrator of medical schemes.



INDICATION	PRODUCT NAME	CLINICAL CRITERIA
Malignant melanoma	Yervoy	Advanced (unresectable or metastatic) malignant melanoma
	Keytruda	Adjuvant malignant melanoma and with lymph node involvement and following complete resection
	Keytruda	Advanced (unresectable or metastatic) malignant melanoma
Multiple myeloma	Darzalex	Multiple myeloma and after at least three prior lines of therapy (including a proteasome inhibitor and immunomodulatory agent) or who are double refractory to PI and immunomodulatory agent
Chronic lymphocytic leukemia	Imbruvica	Chronic lymphocytic leukaemia and as first line therapy or treatment for relapsed (refractory) disease
	Venclexta	Chronic lymphocytic leukemia in combination with obinituzumab and as first line therapy
	Venclexta	Chronic lymphocytic leukemia in combination with rituximab and after at least one prior therapy
Waldenstrom macroglobulinemia	Imbruvica	Waldenstrom macroglobulinemia and as first line therapy or relapsed disease and after treatment with a rituximab-containing regimen
Mantle cell lymphoma	Imbruvica	Mantle cell lymphoma (MCL) and after treatment with at least one prior therapy
T-cell Lymphoma	Adcetris	Cutaneous T-cell lymphoma and in combination with Doxorubicin, Cyclophosphomide and Prednisone and previously treated (relapsed disease) and CD-30 positive
	Adcetris	Cutaneous T-cell lymphoma and in combination with Doxorubicin, Cyclophosphomide and Prednisone and as first line therapy and CD-30 positive
Hodgkin's Lymphoma	Adcetri	Hodgkin's lymphoma and as consolidation therapy after autologous stem-cell transplantation and at risk of relapse or progression
Thyroid Cancer	Lenvima	Progressive locally advanced or metastatic differentiated thyroid cancer (DTC) and radioactive iodine (RAI) refractory
Renal Cell Carcinoma	Lenvima	Advanced renal cell carcinoma (RCC) and and in combination with everolimus and after one prior antiangiogenic therapy
Metastatic Breast Cancer	Tecentriq	Unresectable locally advanced or metastatic Triple Negative Breast Cancer and in combination with nab-paclitaxel and as first line therapy and whose tumours express PD-L1 $\geq 1\%$

ONCOLOGY INNOVATION BENEFIT

Discovery Health Medical Scheme, registration number 1125, is regulated by the Council for Medical Schemes and administered by Discovery Health (Pty) Ltd, registration number 1997/013480/07, an authorised financial services provider. Find a healthcare provider, Discovery MedXpress and the Discovery app are brought to you by Discovery Health (Pty) Ltd; registration number 1997/013480/07, an authorised financial services provider and administrator of medical schemes.



Defined medicines are covered from the Oncology Innovation Benefit for the Classic Smart Comprehensive, Priority, Saver, Smart and Core Plans

INDICATION	PRODUCT NAME	CLINICAL CRITERIA
Locally advanced or metastatic non-small cell lung cancer	Keytruda	Metastatic non-small cell lung carcinoma (NSCLC) and as first line therapy and whose tumours express PD-L1 with a $\geq 50\%$ and with no EGFR or ALK genomic tumour aberrations
	Tagrisso	Locally advanced or metastatic non-small cell lung cancer (NSCLC) and as second line therapy (after EGFR TKI therapy) and EGFR T790M mutation-positive
	Xalkori	Advanced non-small cell lung carcinoma (NSCLC) and whose tumours are ALK positive and as first line therapy or second line therapy after failure of systemic chemotherapy

Use our designated service providers (DSPs)

You have full cover in our designated service provider (DSP) networks and for providers who we have a payment arrangement with. You should use our pharmacy designated service provider (DSP) for approved oncology medicine. Speak to your treating doctor and confirm that they are using our designated service providers (DSPs) for your medicine received for treatment in-rooms or in a treatment facility.

For approved oncology-related medicine where the doctor provides you with a prescription, you should use MedXpress or a MedXpress Network Pharmacy. To find a MedXpress Network Pharmacy visit www.discovery.co.za under Medical aid > Find a healthcare provider or click on Find a provider on the Discovery app.

Discovery MedXpress is a convenient medicine ordering service that provides seamless ordering of prescribed medicine via SMS, the Discovery website and the mobile app. You can get your monthly chronic medicine delivered to your door or collect your medicine in-store at a participating pharmacy at no extra cost to you. Learn more about the benefits of using MedXpress and how to order your medicine [here](#).



Contact us

Tel (members): 0860 99 88 77, Tel (health partners): 0860 44 55 66

Go to www.discovery.co.za to Get Help or ask a question on WhatsApp. Save this number 0860 756 756 on your phone and say "Hi" to start chatting with us 24/7.

PO Box 784262, Sandton, 2146. 1 Discovery Place, Sandton, 2196.

Complaints process

Discovery Health Medical Scheme is committed to providing you with the highest standard of service and your feedback is important to us. The following channels are available for your complaints and we encourage you to follow the process:

1 | STEP 1 – TO TAKE YOUR QUERY FURTHER:

If you have already contacted the Discovery Health Medical Scheme and feel that your query has still not been resolved, please complete our online complaints form on www.discovery.co.za. We would also love to hear from you if we have exceeded your expectations.

2 | STEP 2 – TO CONTACT THE PRINCIPAL OFFICER:

If you are still not satisfied with the resolution of your complaint after following the process in Step 1 you are able to escalate your complaint to the Principal Officer of the Discovery Health Medical Scheme. You may lodge a query or complaint with Discovery Health Medical Scheme by completing the online form on www.discovery.co.za or by emailing principalofficer@discovery.co.za.

3 | STEP 3 – TO LODGE A DISPUTE:

If you have received a final decision from Discovery Health Medical Scheme and want to challenge it, you may lodge a formal dispute. You can find more information of the Scheme's dispute process on the website.

4 | STEP 4 – TO CONTACT THE COUNCIL FOR MEDICAL SCHEMES:

Discovery Health Medical Scheme is regulated by the Council for Medical Schemes. You may contact the Council at any stage of the complaints process, but we encourage you to first follow the steps above to resolve your complaint before contacting the Council.

Contact details for the Council for Medical Schemes: Council for Medical Schemes Complaints Unit, Block A, Eco Glades 2 Office Park, 420 Witch-Hazel Avenue, Eco Park, Centurion 0157 | complaints@medicalschemes.co.za | 0861 123 267 | www.medicalschemes.co.za